Exp Clin Endocrinol Diabetes 2019; 127(04): 255-262
DOI: 10.1055/s-0043-125324
Article
© Georg Thieme Verlag KG Stuttgart · New York

Intravenous Injection of miR-34a Inhibitor Alleviates Diabetes Mellitus-Induced Vascular Endothelial Dysfunction by Targeting NOTCH1

Authors

  • Di Zhao

    2   Department of Orthopedics, the First Affiliated Hospital of Shantou University Medical College, Shantou, China
  • Na-Sui Wang

    1   Division of Endocrinology and Metabolism, Department of Medicine, the First Affiliated Hospital of Shantou University Medical College, Shantou, China
  • Fu Chen

    1   Division of Endocrinology and Metabolism, Department of Medicine, the First Affiliated Hospital of Shantou University Medical College, Shantou, China
  • Zheng-Bing Li

    1   Division of Endocrinology and Metabolism, Department of Medicine, the First Affiliated Hospital of Shantou University Medical College, Shantou, China
  • Xi-Tao Li

    1   Division of Endocrinology and Metabolism, Department of Medicine, the First Affiliated Hospital of Shantou University Medical College, Shantou, China
  • Xu-Xin Zhu

    1   Division of Endocrinology and Metabolism, Department of Medicine, the First Affiliated Hospital of Shantou University Medical College, Shantou, China
Further Information

Publication History

received 30 November 2017
revised 30 November 2017

accepted 21 December 2017

Publication Date:
12 March 2018 (online)

Preview

Abstract

Background miR-34a is a multifunctional post-translational modulator, which is involved in several diabetes-related complications. However, miR-34a remains to be fully elucidated in the diabetic endothelium from rats. In this study, the role of miR-34a/NOTCH1 signaling in the progression of hyperglycemia-vascular endothelial dysfunction was investigated.

Methods In intravenous injection of miR-34a mimics and inhibitors in streptozotocin (STZ)-induced diabetic rats, the biomarkers of endothelial dysfunction was measured. The targeted genes were predicted by a bioinformatics algorithm and confirmed by a dual luciferase reporter assay. The mRNA and protein levels were assayed by qRT-PCR and western blotting, respectively. Immunohistochemical staining was performed to measure NOTCH1 expression in the diabetic endothelium.

Results miR-34a was significantly up-regulated, and NOTCH1 down-regulated, in the thoracic aorta from STZ-induced diabetic rats compared with control group. As compared to model group, the mRNA of NOTCH1 was significantly decreased or increased by miR-34a mimics or inhibitors ex vivo, respectively. Bioinformatics methods further demonstrated that NOTCH1 was a potential target of miR-34a, which was confirmed by dual-luciferase reporter assay. Moreover, both serum ET and NO were significantly increased in diabetic rats as compared to control group. miR-34a inhibitors ex vivo treatment resulted in significant down-regulation ofserum ET and NO levels in diabetic rats as compared to model group.

Conclusion These results provide evidence to support the use of miR-34a inhibitors as a therapeutic approach attenuating hyperglycemia-induced vascular endothelial dysfunction.